Using both in vitro and preclinical models, they reported that ACC inhibition (pharmacologically and genetically) reduced de novo lipids synthesis and decreased the growth and viability of non-small-cell lung cancer cells. This evidence concerns the gene ACACA and non-small cell lung carcinoma.